T cell reactivation was caused by EGCG’s ability to reduce PD-L1 expression and inhibit JAK/STAT signaling in tumor cells, whereas anti-PD-1 therapy interrupted the interplay between PD-1 and PD-L1. Here, CD274 is linked to neoplasm.